Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

NCT00171977 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Imatinib Mesylate

Sponsor

Novartis Pharmaceuticals